ACSL4 modulated aberrant lipid metabolism (28) and survival outcome of HCC patients and was validated as a predictive biomarker of sorafenib-induced ferroptosis in HCC (43). This evidence concerns the gene ACSL4 and hepatocellular carcinoma.